CN112691150A - 一种组合物及其制备方法和应用 - Google Patents
一种组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN112691150A CN112691150A CN202110122481.3A CN202110122481A CN112691150A CN 112691150 A CN112691150 A CN 112691150A CN 202110122481 A CN202110122481 A CN 202110122481A CN 112691150 A CN112691150 A CN 112691150A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- vitamin
- juice
- tomato
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 244000010000 Hovenia dulcis Species 0.000 claims abstract description 63
- 235000008584 Hovenia dulcis Nutrition 0.000 claims abstract description 63
- 235000013305 food Nutrition 0.000 claims abstract description 61
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims abstract description 60
- 240000003768 Solanum lycopersicum Species 0.000 claims abstract description 60
- 241001018563 Nekemias grossedentata Species 0.000 claims abstract description 45
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 32
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 22
- 231100000753 hepatic injury Toxicity 0.000 claims abstract description 21
- 206010067125 Liver injury Diseases 0.000 claims abstract description 20
- 230000001476 alcoholic effect Effects 0.000 claims abstract description 17
- 208000024891 symptom Diseases 0.000 claims abstract description 17
- 230000035622 drinking Effects 0.000 claims abstract description 11
- 239000000284 extract Substances 0.000 claims description 67
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 50
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 47
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 40
- 239000000843 powder Substances 0.000 claims description 38
- 238000002156 mixing Methods 0.000 claims description 32
- 235000006708 antioxidants Nutrition 0.000 claims description 31
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 23
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 22
- 229930091371 Fructose Natural products 0.000 claims description 22
- 239000005715 Fructose Substances 0.000 claims description 22
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 22
- 229930003268 Vitamin C Natural products 0.000 claims description 22
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 22
- 235000019154 vitamin C Nutrition 0.000 claims description 22
- 239000011718 vitamin C Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 19
- 229930003427 Vitamin E Natural products 0.000 claims description 19
- 239000008103 glucose Substances 0.000 claims description 19
- 229940046009 vitamin E Drugs 0.000 claims description 19
- 235000019165 vitamin E Nutrition 0.000 claims description 19
- 239000011709 vitamin E Substances 0.000 claims description 19
- 235000013399 edible fruits Nutrition 0.000 claims description 18
- 210000000582 semen Anatomy 0.000 claims description 18
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 17
- 235000019158 vitamin B6 Nutrition 0.000 claims description 17
- 239000011726 vitamin B6 Substances 0.000 claims description 17
- 229940011671 vitamin b6 Drugs 0.000 claims description 17
- 239000007787 solid Substances 0.000 claims description 12
- 235000015193 tomato juice Nutrition 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- -1 glidants Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 150000003700 vitamin C derivatives Chemical class 0.000 claims description 9
- 241000563984 Ampelopsis Species 0.000 claims description 8
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 claims description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 8
- 235000013361 beverage Nutrition 0.000 claims description 8
- 239000002738 chelating agent Substances 0.000 claims description 8
- 239000003086 colorant Substances 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 229960002737 fructose Drugs 0.000 claims description 8
- 239000003381 stabilizer Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 7
- 235000000346 sugar Nutrition 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 5
- 235000009508 confectionery Nutrition 0.000 claims description 5
- 235000013402 health food Nutrition 0.000 claims description 5
- 235000015110 jellies Nutrition 0.000 claims description 5
- 239000008274 jelly Substances 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 208000032140 Sleepiness Diseases 0.000 claims description 4
- 206010041349 Somnolence Diseases 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000007884 disintegrant Substances 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 229960001031 glucose Drugs 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000000080 wetting agent Substances 0.000 claims description 4
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 claims description 3
- 206010047700 Vomiting Diseases 0.000 claims description 3
- 208000002173 dizziness Diseases 0.000 claims description 3
- 230000008673 vomiting Effects 0.000 claims description 3
- 239000001692 EU approved anti-caking agent Substances 0.000 claims description 2
- 230000002421 anti-septic effect Effects 0.000 claims description 2
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000007888 film coating Substances 0.000 claims description 2
- 238000009501 film coating Methods 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 235000021022 fresh fruits Nutrition 0.000 claims description 2
- 238000000265 homogenisation Methods 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 238000005057 refrigeration Methods 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 244000269722 Thea sinensis Species 0.000 claims 2
- 230000003064 anti-oxidating effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000009098 adjuvant therapy Methods 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 38
- 229940079593 drug Drugs 0.000 abstract description 8
- 238000012360 testing method Methods 0.000 description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 40
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 32
- 239000000047 product Substances 0.000 description 31
- 150000003254 radicals Chemical class 0.000 description 28
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 24
- 235000013373 food additive Nutrition 0.000 description 23
- 239000002778 food additive Substances 0.000 description 23
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 description 21
- 241001122767 Theaceae Species 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 19
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 18
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 18
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 18
- 235000012661 lycopene Nutrition 0.000 description 18
- 229960004999 lycopene Drugs 0.000 description 18
- 239000001751 lycopene Substances 0.000 description 18
- 229940118019 malondialdehyde Drugs 0.000 description 18
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 17
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 17
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 17
- 239000013641 positive control Substances 0.000 description 17
- 210000004185 liver Anatomy 0.000 description 16
- 238000011160 research Methods 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- 102000019197 Superoxide Dismutase Human genes 0.000 description 13
- 108010012715 Superoxide dismutase Proteins 0.000 description 13
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 13
- 230000036541 health Effects 0.000 description 11
- 239000008213 purified water Substances 0.000 description 11
- 239000007901 soft capsule Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 210000005228 liver tissue Anatomy 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 10
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000035987 intoxication Effects 0.000 description 8
- 231100000566 intoxication Toxicity 0.000 description 8
- 229920000881 Modified starch Polymers 0.000 description 7
- 229960003180 glutathione Drugs 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 210000005229 liver cell Anatomy 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000001509 sodium citrate Substances 0.000 description 7
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 7
- 235000015112 vegetable and seed oil Nutrition 0.000 description 7
- 235000013871 bee wax Nutrition 0.000 description 6
- 239000012166 beeswax Substances 0.000 description 6
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 239000001814 pectin Substances 0.000 description 6
- 235000010987 pectin Nutrition 0.000 description 6
- 229920001277 pectin Polymers 0.000 description 6
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 6
- 208000007848 Alcoholism Diseases 0.000 description 5
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 5
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 5
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000004376 Sucralose Substances 0.000 description 5
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 5
- 229940066595 beta tocopherol Drugs 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 235000010389 delta-tocopherol Nutrition 0.000 description 5
- 229930003935 flavonoid Natural products 0.000 description 5
- 235000017173 flavonoids Nutrition 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 5
- 235000019408 sucralose Nutrition 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 239000011590 β-tocopherol Substances 0.000 description 5
- 235000007680 β-tocopherol Nutrition 0.000 description 5
- 239000002446 δ-tocopherol Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 4
- 206010019708 Hepatic steatosis Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 235000010382 gamma-tocopherol Nutrition 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229940092258 rosemary extract Drugs 0.000 description 4
- 235000020748 rosemary extract Nutrition 0.000 description 4
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 235000010378 sodium ascorbate Nutrition 0.000 description 4
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 4
- 229960005055 sodium ascorbate Drugs 0.000 description 4
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 229940042585 tocopherol acetate Drugs 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- 239000002478 γ-tocopherol Substances 0.000 description 4
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 4
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 description 3
- SERLAGPUMNYUCK-YJOKQAJESA-N 6-O-alpha-D-glucopyranosyl-D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-YJOKQAJESA-N 0.000 description 3
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 3
- 235000017491 Bambusa tulda Nutrition 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 244000082204 Phyllostachys viridis Species 0.000 description 3
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 3
- 239000004260 Potassium ascorbate Substances 0.000 description 3
- 244000272459 Silybum marianum Species 0.000 description 3
- 235000010841 Silybum marianum Nutrition 0.000 description 3
- 206010001584 alcohol abuse Diseases 0.000 description 3
- 208000025746 alcohol use disease Diseases 0.000 description 3
- 239000011425 bamboo Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 235000010376 calcium ascorbate Nutrition 0.000 description 3
- 229940047036 calcium ascorbate Drugs 0.000 description 3
- 239000011692 calcium ascorbate Substances 0.000 description 3
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 3
- 235000021466 carotenoid Nutrition 0.000 description 3
- 150000001747 carotenoids Chemical class 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 239000005417 food ingredient Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 235000019534 high fructose corn syrup Nutrition 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 239000008601 oleoresin Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 235000019275 potassium ascorbate Nutrition 0.000 description 3
- 229940017794 potassium ascorbate Drugs 0.000 description 3
- CONVKSGEGAVTMB-RXSVEWSESA-M potassium-L-ascorbate Chemical compound [K+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] CONVKSGEGAVTMB-RXSVEWSESA-M 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 229940026314 red yeast rice Drugs 0.000 description 3
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 3
- 229940048086 sodium pyrophosphate Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 3
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 3
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 3
- DBSABEYSGXPBTA-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DBSABEYSGXPBTA-RXSVEWSESA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 235000010955 Hovenia acerba Nutrition 0.000 description 2
- 241001533134 Hovenia acerba Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 244000288157 Passiflora edulis Species 0.000 description 2
- 235000000370 Passiflora edulis Nutrition 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000219100 Rhamnaceae Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 2
- 229940071097 ascorbyl phosphate Drugs 0.000 description 2
- 239000004204 candelilla wax Substances 0.000 description 2
- 235000013868 candelilla wax Nutrition 0.000 description 2
- 229940073532 candelilla wax Drugs 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 235000005686 eating Nutrition 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000012847 fine chemical Substances 0.000 description 2
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000000905 isomalt Substances 0.000 description 2
- 235000010439 isomalt Nutrition 0.000 description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000004783 oxidative metabolism Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 235000015113 tomato pastes and purées Nutrition 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 244000189799 Asimina triloba Species 0.000 description 1
- 235000006264 Asimina triloba Nutrition 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 235000007270 Gaultheria hispida Nutrition 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 235000008586 Hovenia Nutrition 0.000 description 1
- 241000405398 Hovenia Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 241000227653 Lycopersicon Species 0.000 description 1
- 235000002262 Lycopersicon Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 235000009134 Myrica cerifera Nutrition 0.000 description 1
- 244000269152 Myrica pensylvanica Species 0.000 description 1
- 235000012851 Myrica pensylvanica Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 235000003953 Solanum lycopersicum var cerasiforme Nutrition 0.000 description 1
- 240000003040 Solanum lycopersicum var. cerasiforme Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- MIJPAVRNWPDMOR-UHFFFAOYSA-N [2-(1,2-dihydroxyethyl)-3-hydroxy-5-oxo-2h-furan-4-yl] dihydrogen phosphate Chemical compound OCC(O)C1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- 230000010227 extrahepatic metabolism Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000021433 fructose syrup Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 231100000832 liver cell necrosis Toxicity 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 229940057059 monascus purpureus Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000004320 sodium erythorbate Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/368—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/42—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/10—Marmalades; Jams; Jellies; Other similar fruit or vegetable compositions; Simulated fruit products
- A23L21/15—Marmalades; Jams; Jellies; Other similar fruit or vegetable compositions; Simulated fruit products derived from fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于医药或食品领域,具体涉及一种组合物,包含0.2~280重量份的枳椇子,0.2~300重量份的番茄;0.1~150重量份藤茶;还涉及该组合物的制备方法及应用。本发明组合物具有抗氧化的功能,并且,本发明组合物对酒精性肝损伤有改善治疗作用,对饮酒引起的不适症状有良好改善效果。
Description
技术领域
本发明属于医药或食品领域,具体涉及一种组合物,还涉及该组合物的制备方法及其在医药或食品中的应用。
背景技术
自由基(Freeradicals)也称为“游离基”,是含有不成对电子的原子团。由于原子形成分子时,化学键中电子必须成对出现,因此自由基夺取其他物质的单个电子,使自身形成稳定的物质,这种现象被称为“氧化”。
自由基具有强氧化性,如体内自由基数量过多会引起脂质过氧化,对生物膜和其他组织造成损伤,破坏细胞结构,使组织细胞失去正常功能,甚至破坏DNA,进而引发多种慢性疾病及加速衰老。正常情况下,人体内存在一定的抗氧化剂,它们能清除过多的自由基,使体内自由基的生成和清除处于动态平衡。如果自由基产生过多和清除自由基能力下降,体内就会有多余的自由基(特别是氧自由基Oxygen-free radical),会损伤细胞成分,但还没有出现疾病的症状,如果不加以调整,继续发展下去就会导致疾病和衰老的发生,这时需要从体外补充抗氧化剂,帮助达到体内自由基的平衡,从而预防疾病的发生。
研究发现,25岁左右时,人体内的抗氧化剂最丰富,以后逐渐减少,过了40岁,减少速度加快,如不及时从体外补充抗氧化剂,人体就容易产生疾病,甚至加快衰老。此外,当人体处于疾病状态,或存在紧张、忧愁、激烈运动、吸烟、过度饮酒等因素,或受到紫外线照射、放射线照射、环境污染等因素的作用时,也会引起自由基产生过量,若此时体内的抗氧化剂不足,无法清除过多的自由基,就会导致人体健康受损。大量研究表明,炎症、肿瘤、衰老、血液病,以及心、肝、肺、皮肤疾病的发生机制与体内过多的自由基、自由基浓度及抗氧化作用的失衡有关。
近年,随着生活水平的提高,人们饮食习惯、生活习惯的改变,慢性病的发生率越来越高。在影响人类的健康长寿的因素中,85%来自自由基的侵害,研究证实:有超过100种疾病与自由基产生过量或人体自身清除自由基能力下降有关,酒精性肝损伤是其中之一。
酒精(乙醇)性肝损伤是由于长期大量饮酒导致的肝脏损伤疾病。初期通常表现为脂肪肝,进而可发展成酒精性肝炎、肝纤维化和肝硬化。严重酗酒时可诱发广泛肝细胞坏死,甚至肝功能衰竭。
很多临床研究表明:乙醇导致的肝脂肪变性与自由基增多有关。乙醇代谢使肝细胞氧化还原反应增高,此反应中自由基产生亦增多,抑制了脂肪酸氧化,致使肝细胞脂肪蓄积。乙醛可促进乙醇诱导自由基生成增加,同时,乙醛可增加肝脏脂质过氧化物含量,降低肝脏谷胱甘肽水平。饮酒过度可激活产生氧自由基和乙醛物质的系统,对肝脏造成损伤。
酒中的乙醇进入体内后通过胃肠道吸收,仅有2%-10%由呼吸道、尿液和汗腺以原形排出,其余90%在肝脏内氧化代谢,很少在肝外代谢;经肝脏代谢的乙醇约80%通过乙醇脱氢酶转化为乙醛,约20%通过微粒体乙醇氧化酶转化为乙醛,乙醛再经过乙醛脱氢酶(ALDH)转化为乙酸,乙酸以乙酰CoA的形式进入三羧酸循环,氧化成二氧化碳和水。
乙醛是一种高活性物质,与酒精性肝损伤的发展密切相关。肝细胞线粒体内的乙醛可被ALDH氧化为乙酸,当ALDH活性降低时,未被氧化的乙醛进入血内,通过黄嘌呤氧化酶转变为超氧化物,导致脂质过氧化,破坏细胞膜脂质,促进肝损伤。另外,乙醛可作用于线粒体、微管及质膜等,引起肝细胞退变。同时有研究发现ALDH活性的减弱与肝损伤的程度是平行发展的,乙醛可使肝细胞内线粒体受损,从而使肝细胞对脂肪酸分解功能低下,此时机体可动员皮下脂肪组织的脂肪酸向肝内转移,久而久之形成脂肪肝。
乙醛还可与各种蛋白质相结合形成一种络合物,即乙醛复合体,这些络合物作为一个新的抗原刺激物,导致肝细胞再度受损。该络合物是乙醇诱导氧化应激反应的结果。乙醇滥用可激活产生氧自由基和乙醛物质的系统,在这个过程中产生的乙醛和脂质过氧化物能与蛋白质结合形成稳定的络合物,络合物的形成导致蛋白质功能的紊乱、刺激纤维生成及诱导免疫应答。在乙醇滥用患者肝损伤早期,组织病理学发现肝小叶中心的蛋白质络合物是酒精性肝疾病发病机制的主要因素。另外,乙醛的氧化代谢还可促使活性氧的产生,氧自由基增多,进而造成肝细胞损伤及坏死。
有害饮酒已被世界卫生组织(WHO)列入全球过早死亡和致残的第五大主要危险因素,酒精性肝损伤疾病也是我国常见的肝脏疾病之一,严重危害人民健康。
对于“自由基”引起的“氧化”,以及乙醇代谢引发自由基、乙醛增多导致的肝损伤疾病,除了医疗药物干预、改变习惯外,另一个重要的方法是体外补充抗氧化剂,对抗氧化剂的研究是技科研技术研究热点之一。
抗氧化剂的种类很多,如维生素E、维生素C、辅酶Q10、多酚、番茄红素、虾青素、类胡萝卜素等。目前的很多研究报道多为单一物质的研究报道,相互间有协同作用的研究不多见。
枳椇子为鼠李科(Rhamnaceae)枳椇属枳椇(HoveniaacerbaLindl.)的果实或种子,俗称拐枣、金钩子、鸡爪梨、树蜜、万寿果等,是我国卫生部首批公布的新资源食品,我国绝大多数省区均有分布。枳椇子在我国历史久远,《诗经》、《礼记》、《庄子》中均记载。不仅食用亦可入药,中医认为枳椇子具有清热利尿,解酒毒之功效,主治醉酒、烦热、口渴、呕吐、二便不利等症。枳椇子药用始载于《唐本草》,李时珍称它为金果树,并收载入《本草纲目》等多种中医药典籍。
研究发现,枳椇子中含有丰富的碳水化合物、粗蛋白、粗脂肪和粗纤维,必需氨基酸占氨基酸总量的35%,含有K、Ca、Mg、Na、Fe、Mn、Cu、Zn等多种矿物质;脂肪中亚麻酸占约40%;黄酮类占约2.8%。新鲜的枳椇子也可榨汁、可做果酱、可干燥、可经提取做成提取物。枳椇提子取物的标志性成分为黄酮类化合物或二氢杨梅素,含量有多种规格;也有以多糖为标志成分的。现代医学认为,枳椇子具有利尿、解酒护肝、抗肿瘤等作用,提取物效果更优。
番茄(LycopersiconesculentumMill),俗称西红柿,是管状花目、茄科、番茄属草本植物番茄成熟的果实,是生活中常见的果菜之一。番茄含有丰富的维生素、矿物质、糖类、有机酸和果胶等,特别是类胡萝卜素含量高。番茄营养丰富,可以生食、煮食、加工成番茄酱、番茄汁或干燥磨粉或做成提取物食用。
番茄红素是番茄中类胡萝卜素的重要成分之一,番茄鲜果含水80-95%,番茄红素含量较低,据报道不同品种和成熟度差异较大,一般约0.3mg/100g至4.2mg/100g不等。通常黄色番茄番茄红素含量最低,粉色次之,红色较高;樱桃番茄高于普通番茄;番茄汁/酱含量可达9.3-29mg/100g,番茄皮中含量最高可达80-90mg/100g,通过有机溶剂提取或超临界二氧化碳萃取或再经纯后制取不同番茄红素含量的番茄提取物。
番茄红素在体内主要储藏于肝脏,很多研究表明番茄红素具有多种生理功能。李京,惠伯棣等在《番茄红素一被关注的功能因子》(食品科学,2005年08期)一文中报道:番茄红素具有抗氧化,抗癌、预防种瘤,免疫调节,抗疲劳等功能。番茄红素不仅可用作食品天然色素,而且也已越来越多地应用于功能食品、药品和化妆品中。
藤茶又叫莓茶、龙须茶等,学名为显齿蛇葡萄叶,是葡萄科蛇葡萄属显齿蛇葡萄(Ampelopsisgrossedentata)的叶子,国家卫生卫计委2013年第16号公告公布的新食品原料。藤茶嫩叶可直接加水榨汁,可干燥后冲泡,也可用水或乙醇或其他溶剂提取,或再经纯化做成不同规格含量的提取物。藤茶嫩叶经过杀青、揉捻、烘干而成的类似茶叶的产品称为藤茶。藤茶具有一定的药用价值,《中华本草》记载:藤茶,性凉;味苦,微涩;有清热利湿;平肝降压;活血通络等功效。刘慧颖等(《显齿蛇葡萄的化学成分及药理作用研究进展》,安徽农业科学,2016,44(27))报道:藤茶具有抗氧化、抑菌抗病毒、抗炎镇痛、抗癌、降血脂、降血糖,保肝、增强免疫等多方面的作用。
现代研究发现,藤茶中含有黄酮类化合物、酚类、氨基酸及微量元素、多糖、甾体及萜类化合物,挥发油等成分,黄酮类化合物的含量较高,约为45%,二氢杨梅素含量为2.5-40%。二氢杨梅素通常作为藤茶提取物的标志成分,二氢杨梅素又叫蛇葡萄素、白蔹素,化学名为(2R,3R)-3,5,7-三羟基-2-(3,4,5-三羟基苯基)苯并二氢吡喃-4-酮,分子式为C15H12O8,具有抗氧化、抗肿瘤、抗炎、解酒保肝、抗病原微生物及调血脂、降高血压、抑制血栓形成、降血糖等多方面的药理作用。
发明内容
本发明提供了一种组合物,本发明组合物具有抗氧化的功能,组合物原料间有协同作用,能增强整体抗氧化效果。并且,本发明组合物对酒精性肝损伤有改善/治疗作用,对饮酒引起的不适症状有良好改善效果。在此基础上,本发明还提供了一种药物和一种保健食品或健康食品。
本发明第一方面涉及一种组合物,包含:
枳椇子0.2~280重量份(例如0.2重量份、0.3重量份、0.6重量份、1重量份、2重量份、3重量份、8重量份、10重量份、15重量份、20重量份、30重量份、50重量份、60重量份、80重量份、100重量份、130重量份、140重量份、150重量份、155重量份、160重量份、166重量份、170重量份、175重量份、180重量份、186重量份、190重量份、200重量份、220重量份、240重量份、250重量、270重量、280重量份)
番茄0.2~300重量份(例如0.2重量份、0.4重量份、0.6重量份、0.8重量份、1重量份、3重量份、6重量份、8重量份、10重量份、13重量份、15重量份、20重量份、30重量份、50重量份、60重量份、80重量份、100重量份、120重量份、150重量份、155重量份、160重量份、163重量份、168重量份、170重量份、180重量份、186重量份、190重量份、200重量份、220重量份、240重量份、260重量份、280重量份、300重量份)
藤茶0.1~150重量份(例如0.1重量份、0.2重量份、0.5重量份、0.8重量份、1重量份、2重量份、3重量份、5重量份、6重量份、8重量份、10重量份、13重量份、18重量份、20重量份、30重量份、40重量份、60重量份、70重量份、75重量份、80重量份、85重量份、88重量份、90重量份、93重量份、95重量份、97重量份、98重量份、99重量份、100重量份、120重量份、140重量份、150重量份)。
本发明第一方面的一个实施方式中,所述组合物包含:
枳椇子0.3~250重量份;
番茄0.25~250重量份;
藤茶0.15~120重量份。
本发明第一方面的一个实施方式中,所述枳椇子以枳椇子鲜果、枳椇子果汁(原汁和/或浓缩汁)、枳椇子果酱、枳椇子果汁粉、枳椇子粉、枳椇子提取物中的至少一种形式提供,优选的所述枳椇子包含枳椇子果汁、枳椇子粉、枳椇子提取物中的至少一种;其中枳椇子提取物为用水或乙醇或其他溶剂或组合溶剂提取或再经纯化。
本发明第一方面的一个实施方式中,所述茄包含番茄鲜果、番茄果汁(原汁和/或浓缩汁)、番茄果酱、番茄果汁粉、番茄粉、番茄提取物中的至少一种;优选的所述番茄包含番茄果汁、番茄粉、番茄提取物中的至少一种;其中番茄提取物是指以番茄红素为标志成分的番茄提取物,以油树脂、粉末/晶体/颗粒的形式提供;优选地,提取物中番茄红素的含量为1%-99.9%,更优选为1%、2%、5%、8%、10%、20%、40%、50%、70%、90%、95%、98%、99%。
本发明第一方面的一个实施方式中,所述藤茶包含鲜藤茶以及由其嫩叶加工而成的藤茶汁(原汁和/或浓缩汁)、藤茶汁粉、藤茶、藤茶粉、藤茶提取物中的至少一种;优选的所述藤茶包含藤茶汁、藤茶粉、藤茶提取物中的至少一种。其中藤茶提取物是包含以二氢杨梅素或黄酮类化合物为主要成分的藤茶提取物;优选地,提取物中二氢杨梅素的含量为10%-99.9%,更优选为10%、15%、20%、25%、30%、40%、50%、60%、75%、90%、95%、98%、99%。
本发明第一方面的一个实施方式中,所述组合物还包含选自维生素C和/或其盐和/或其衍生物,果葡糖(糖粉或/和糖浆,下同),葡萄糖,果糖,维生素B6,维生素E中的至少一种;
本发明第一方面的一个实施方式中,所述组合物还包含维生素C和/或其盐和/或其衍生物、果葡糖和/或和葡萄糖/或果糖。
本发明第一方面的一个实施方式中,所述组合物还包含维生素B6。
本发明第一方面的一个实施方式中,所述组合物还包含维生素C衍生物、维生素E。
本发明第一方面的一个实施方式中,包括如下1)至4)中的一项或多项:
1)所述维生素C和/或其盐为0.005~15重量份,优选为0.01~10重量份,例如0.01重量份、0.013重量份、0.02重量份、0.027重量份、0.03重量份、0.033重量份、0.04重量份、0.046重量份、0.05重量份、0.055重量份、0.06重量份、0.066重量份、0.07重量份、0.08重量份、0.083重量份、0.09重量份、0.1重量份、0.11重量份、0.12重量份、0.13重量份、0.14重量份、0.15重量份、0.155重量份、0.16重量份、0.1.8重量份、0.2重量份、0.2.4重量份、0.3重量份、0.3.6重量份、0.38重量份、0.4重量份、0.42重量份、0.5重量份、0.7重量份、1重量份、1.5重量份、2重量份、2.2重量份、2.6重量份、3重量份、3.6重量份、4重量份、4.5重量份、5重量份、6重量份、7重量份、8重量份、9重量份、10重量份;
2)所述果葡糖和/或果糖和/或葡萄糖为1~600重量份,优选为4~400重量份,例如4重量份、7重量份、10重量份、15重量份、23重量份、30重量份、40重量份、50重量份、60重量份、70重量份、80重量份、100重量份、130重量份、140重量份、160重量份、170重量份、180重量份、200重量份、210重量份、230重量份、240重量份、250重量份、270重量份、280重量份、300重量份、320重量份、370重量份、400重量份;
3)所述维生素B6为0.0004~0.3重量份,优选为0.0005~0.2重量份,例如0.0005重量份、0.0006重量份、0.0008重量份、0.001重量份、0.0015重量份、0.002重量份、0.003重量份、0.004重量份、0.005重量份、0.0066重量份、0.008重量份、0.009重量份、份0.01重量份、0.014重量份、0.018重量份、0.02重量份、0.023重量份、0.026重量份、0.03重量份、0.035重量份、0.04重量份、0.047重量份、0.05重量份、0.056重量份、0.06重量份、0.066重量份、0.07重量份、0.076重量份、0.080重量份、0.085重量份、0.09重量份、0.1重量份、0.11重量份、0.12重量份、0.13重量份、0.14重量份、0.15重量份、0.155重量份、0.17重量份、0.18重量份、0.2重量份;
4)所述维生素E为0.001~5重量份,优选为0.003~3重量份,例如0.003重量份、0.004重量份、0.005重量份、0.006重量份、0.008重量份、0.01重量份、0.012重量份、0.016重量份、0.02重量份、0.026重量份、0.03重量份、0.035重量份、0.04重量份、0.046重量份、0.05重量份、0.053重量份、0.06重量份、0.065重量份、0.07重量份、0.076重量份、0.08重量份、0.086重量份、0.09重量份、0.1重量份、0.11重量份、0.12重量份、0.13重量份、0.15重量份、0.156重量份、0.17重量份、0.18重量份、0.2重量份、0.25重量份、0.3重量份、0.33重量份、0.38重量份、0.4重量份、0.46重量份、0.5重量份、0.7重量份、0.8重量份、1重量份、1.2重量份、1.5重量份、1.66重量份、1.9重量份、2重量份、2.2重量份、2.5重量份、2.8重量份、3重量份;
本发明中,所述的维生素C指抗坏血酸或异抗坏血酸中的至少一种。
本发明中,所述的维生素C盐为食品上可接受的维生素C盐或药学上可接受的维生素C盐。包括但不限于维生素C的钠盐、钾盐、钙盐、镁盐、锌盐等等。
本发明中,维生素C衍生物,为食品上可接受的维生素C衍生物或药学上可接受的维生素C衍生物。包括但不限于维生素C磷酸酯、维生素C磷酸盐(如维生素C磷酸酯镁)、维生素C棕榈酸酯、维生素C棕榈酸盐、维生素C琥珀酸酸酯、维生素C琥珀酸酸盐等等。
本发明第一方面的一个实施方式中,所述维生素E选自天然d型α生育酚、天然d型β生育酚、天然d型γ生育酚、天然d型δ生育酚、天然d型α醋酸生育酚、天然d型β醋酸生育酚、天然d型γ醋酸生育酚、天然d型δ醋酸生育酚、天然d型α琥珀酸生育酚、天然d型β琥珀酸生育酚、天然d型γ琥珀酸生育酚、天然d型δ琥珀酸生育酚、混合生育酚、合成dl型α生育酚、合成dl型β生育酚、合成dl型γ生育酚、合成dl型δ生育酚、合成dl型α醋酸生育酚、合成dl型β醋酸生育酚、合成dl型γ醋酸生育酚、合成dl型δ醋酸生育酚、合成dl型α琥珀酸生育酚、合成dl型β琥珀酸生育酚、合成dl型γ琥珀酸生育酚以及合成dl型δ琥珀酸生育酚中的至少一种。
本发明第一方面的一个实施方式中,组合物还包含辅料;优选地,所述辅料选自稀释剂、稳定剂、抗氧化剂、防腐剂、螯合剂、粘合剂、助流剂、矫味剂、着色剂、润湿剂、抗结剂、填充剂、润滑剂、包衣剂(或被膜剂)、崩解剂和载体中的至少一种。
本发明中,所述辅料为食品上可接受的辅料或药学上可接受的辅料。
本发明第二方面涉及一种药物或食品,其包含本发明第一方面中任一所述的组合物。
本发明第二方面的一个实施方式中,所述食品为食品或保健食品。
本发明第二方面的一个实施方式中,所述药物或食品的剂型为饮料、糖果、果冻、片剂、胶囊剂、固体饮料、丸剂。
本发明第三方面涉及制备本发明第一方面中任一所述组合物的方法,其为如下的方法1、方法2;其中,
方法1包括如下步骤:
(1)将枳椇子、番茄分别经榨汁、均质、过滤、离心、加热、溶解中的至少一种工艺处理后,与藤茶,选自维生素C和/或其盐和/或其衍生物、果葡糖、葡萄糖、果糖、维生素B6、维生素E中的至少一种以及选自稀释剂、螯合剂、稳定剂、抗氧化剂中的至少一种进行溶解混合或分步溶解混合,经溶解、离心、过滤、加热、均质中的至少一种工艺处理,得混合物;
(2)将步骤(1)得到的混合物,与选自稀释剂、螯合剂、稳定剂、抗氧化剂、防腐剂、螯合剂、矫味剂、着色剂中的至少一种混合溶解或分步混合溶解,经离心、过滤、均质、冷藏、沉淀、灭菌中的至少一种工艺处理,得混合物;
优选地,方法1中,枳椇子包含枳椇子鲜果、枳椇子果汁、枳椇子提取物中的至少一种;番茄包含番茄鲜果、番茄果汁、番茄提取物中的至少一种;藤茶包含藤茶汁、藤茶汁粉、藤茶提取物中的至少一种。还包括选自维生素C、维生素C盐、果葡糖、葡萄糖、果糖、维生素B6中的至少一种共同混合。
方法2包括如下步骤:
将枳椇子、番茄、藤茶,与选自稀释剂、稳定剂、抗氧化剂、防腐剂、粘合剂、助流剂、矫味剂、着色剂、润湿剂、抗结剂、填充剂、润滑剂、包衣剂(或被膜剂)、崩解剂和载体中的至少一种混合或分步混合。
优选地,方法2中,还包括加入选自维生素C和/或其盐和/或其衍生物,果葡糖,葡萄糖,果糖,维生素B6,维生素E中的至少一种共同混合。
本发明第四方面涉及本发明第一方面中任一所述的组合物在制备抗氧化和/或辅助抗氧化的药物中的用途或者在制备酒精性肝损伤和/或辅助治疗酒精性肝损伤药物中的用途。
本发明第五方面涉及本发明第一方面中任一所述的组合物在制备抗氧化的食品中的用途或者在制预防和/或改善由饮酒等引起的头晕、嗜睡、呕吐等不适症状的食品中的用途或者在制备预防和/或改善酒精性肝损伤的食品中的用途;
优选地,所述食品为保健食品。
如下文献的全文并入本发明:
NY/T 957番茄粉
NY/T 956番茄酱
GB 28316食品安全国家标准食品添加剂番茄红
GB1886.78食品安全国家标准食品添加剂番茄红素(合成)
T/CCCMHPIE 1.28植物提取物番茄红素
GB 14753食品安全国家标准食品添加剂维生素B6(盐酸吡哆醇)
GB14754食品安全国家标准食品添加剂维生素C(抗坏血酸)
GB 1886.44食品安全国家标准食品添加剂抗坏血酸钠
GB 1886.28食品安全国家标准食品添加剂D-异抗坏血酸钠
GB 1886.230食品安全国家标准食品添加剂抗坏血酸棕榈酸酯
GB 1903.24食品安全国家标准食品营养强化剂维生素C磷酸酯镁
YY 0036食品添加剂维生素C磷酸酯镁
GB1886.233食品安全国家标准食品添加剂维生素E
GB/T 26762结晶果糖、固体果葡糖
GB/T 20882果葡糖浆
GB/T 20880食用葡萄糖
GB/T 20885葡萄糖浆
GB/T 317白砂糖
T/CNFIA 110红糖
GB 25531食品安全国家标准食品添加剂三氯蔗糖
GB 1886.182食品安全国家标准食品添加剂异麦芽酮糖
QB/T 4486异麦芽酮糖醇
GB 1886.172食品安全国家标准食品添加剂迷迭香提取物
QB/T 2817食品添加剂迷迭香提取物
GB 30615食品安全国家标准食品添加剂竹叶抗氧化物
SB/T 10198浓缩果汁通用技术条件
GB 1886.87食品安全国家标准食品添加剂蜂蜡
GB/T 24314蜂蜡
SB/T 10190蜂蜡
GB 1886.235食品安全国家标准食品添加剂柠檬酸
GB 1886.25-食品安全国家标准食品添加剂柠檬酸钠
GB/T 38573预糊化淀粉
GB 31637食品安全国家标准食用淀粉
GB 15203食品安全国家标准淀粉糖
GB/T 20884麦芽糊精
GB 1886.91食品安全国家标准食品添加剂硬脂酸镁
GB 25576食品安全国家标准食品添加剂二氧化硅
GB 25533食品安全国家标准食品添加剂果胶
GB 1886.181食品安全国家标准食品添加剂红曲红
GB 1886.19食品安全国家标准食品添加剂红曲米
GB 2716食品安全国家标准植物油
GB 25557食品安全国家标准食品添加剂焦磷酸钠
GB 30616食品安全国家标准食品用香精
卫生卫计委关于批准壳寡糖等6种新食品原料的公告(2014年第6号)
卫生部关于指定D-甘露糖醇等58个食品添加剂产品标准的公告(2011年第8号)
本发明取得的有益效果:
本发明组合物具有抗氧化的功能,组合物原料间有协同作用,能增强整体抗氧化效果。并且,本发明组合物对酒精性肝损伤有改善治疗作用,对饮酒引起的不适症状有良好改善效果。
具体实施方式
以下的实施例、对比例及测试例中使用的材料和试剂如下:
枳椇子果汁:购买自宁夏凯源生物技术有限公司;
枳椇子果汁粉:由枳椇子果汁经干燥自制;
枳椇子粉:购买自安徽馨之源生物科技有限公司;
枳椇子提取物:购买自西安天丰生物科技股份有限公司;
藤茶汁:由腾茶鲜叶经打浆过滤自制;
藤茶汁粉(含二氢杨梅素15%):由腾茶汁经干燥自制;
藤茶粉(含二氢杨梅素25%):购买自湖南甜蔓生物科技有限公司;
藤茶提取物(含二氢杨梅素75%):购买自湖南甜蔓生物科技有限公司;
藤茶提取物(含二氢杨梅素98%):购买自湖南甜蔓生物科技有限公司;
番茄果汁:购买自漳浦县达川食品工业有限公司;
番茄粉:购买自江西雅班那工业有限公司;
番茄提取物(含番茄红素2%,粉):购买自晨光生物科技集团股份有限公司公司;
番茄提取物(含番茄红素10%,粉):购买自晨光生物科技集团股份有限公司公司;
番茄提取物(含番茄红素20%,油树脂):购买自新疆科宇科技公司;
番茄提取物(含番茄红素95%,晶体):购买自乐康瑞德食品添加剂(常州)有限公司;
维生素C(抗环血酸):购买自郑州福润德生物工程有限公司;
维生素C钙(抗环血钙):购买自郑州福润德生物工程有限公司;
维生素C钠(抗环血酸钠):购买自郑州福润德生物工程有限公司;
维生素C钾(抗环血酸钾):购买自郑州福润德生物工程有限公司;
维生素C棕榈酸酯:购买自郑州福润德生物工程有限公司;
维生素C磷酸酯镁:购买自郑州福润德生物工程有限公司;
维生素E:购买自帝斯曼集团;
维生素B6:购买自郑州福润德生物工程有限公司;
果葡糖浆:购买自江苏先卓食品科技股份有限公司;
固体果葡糖:购买自西王药业有限公司;
果糖:购买自山东通升食品配料有限公司;
葡萄糖:购买自山东通升食品配料有限公司;
蔗糖:购买自山东通升食品配料有限公司;
三氯蔗糖:购买自盐城捷康三氯蔗糖制造有限公司
异麦芽酮糖:购买自山东福田药业有限公司;
异麦芽酮糖醇:购买自山东福田药业有限公司;
迷迭香提取物:购买自广州合诚实业有限公司;
竹叶抗氧化物:购买自浙江圣氏生物科技有限公司;
杨梅汁:购买自漳浦县达川食品工业有限公司;
百香果汁:购买自漳浦县达川食品工业有限公司;
蜂蜡:购买自山东东光县隆祥蜂蜡制品有限公司;
小烛树蜡:购买自广州佳琪生物科技有限公司;
柠檬酸:购买自潍坊英轩实业有限公司;
柠檬酸钠:购买自潍坊英轩实业有限公司;
果冻粉:购买自江苏鑫和源生物科技有限公司;
预糊化淀粉:购买自德州高峰淀粉有限公司;
淀粉:购买自罗盖特(中国)精细化工有限公司;
麦芽糊精:购买自罗盖特(中国)精细化工有限公司;
硬脂酸镁:购买自安徽山河药用辅料股份有限公司;
二氧化硅:购买自安徽山河药用辅料股份有限公司;
包衣粉(被膜剂):购买自温州小伦包衣技术有限公司;
果胶:购买自山东安德利集团有限公司;
食用着色剂::购买自上海染料研究所有限公司;
红曲米:购买自杭州天曲生物技术有限公司;
精炼植物油:购买自益海嘉里集团;
水飞蓟籽油:购买自西安瑞尔丽生物工程有限公司;
焦磷酸钠:购买自湖北兴发化工集团股份有限公司;
水果香精:购买自杭州百瑞香精香料有限公司;
清凉剂香精:购买自杭州百瑞香精香料有限公司。
实施例1
将2.5Kg枳椇子果汁、1.2Kg藤茶汁、800g番茄果汁、250g百香果汁,和适量纯化水混匀离心后,清液中加入4Kg果葡糖浆,并加热至70-85℃水,混合均匀,过滤备用。将75g果胶、100g异麦芽酮糖、45g柠檬酸、5g柠檬酸钠,和适量70-85℃纯化水混合,经均质溶解后,与上述过滤后的溶液混合,搅拌均匀;加入100g维生素C钠(抗坏血酸钠)、2g维生素B6、4g竹叶抗氧化物,搅拌溶解,定容至25L,最后加入15g水果香精、4g清凉剂香精,搅拌均匀后经灌装,灭菌,得到饮料产品1。
实施例2
将15Kg枳椇子果汁、25Kg番茄果汁、10Kg杨梅汁、5Kg百香果汁,和适量纯化水混匀离心,在清液中加入400g果葡糖浆、17Kg果糖、50g三氯蔗糖、400g藤茶提取物(98%)、250g焦磷酸钠,并加热至70-85℃水,混合均匀,过滤备用。将1.5Kg果胶、700g柠檬酸、100g柠檬酸钠、12.6Kg葡萄糖,和适量70-85℃纯化水混合,经均质溶解后,与上述过滤后的溶液混合,搅拌均匀,然后加入250g维生素C(抗坏血酸)、30g竹叶抗氧化物;0.8g维生素B6;搅拌溶解,定容至50L,最后加250g水果香精、100g清凉剂香精,搅拌均匀后经灌装,灭菌,得到饮料产品2。
实施例3
将8.5Kg枳椇子粉、9Kg藤茶提取物(98%)、15Kg番茄提取物(10%,粉)、9.4Kg预糊化淀粉、32Kg固体果葡糖、5Kg维生素C、0.6Kg红曲米、80g柠檬酸钠、20g柠檬酸,置于混合机中混合均匀,将混匀后的混合物经制粒后与400g硬脂酸镁总混,总混颗粒经填充胶囊得到硬胶囊1,或将总混颗粒压片并用1.2Kg包衣粉(被膜剂)包衣,得到片剂1。
实施例4
将0.75Kg枳椇子提取物、8.5Kg藤茶提取物(98%)、625g番茄提取物(2%)、500g维生素B6、4.925Kg淀粉、2Kg维生素C磷酸酯镁、80g柠檬酸钠、20g柠檬酸、100g二氧化硅置于混合机中混合均匀,将混匀后的混合物经制粒后经填充胶囊得到硬胶囊2,或将混匀后的混合物添加必要辅料经制丸工艺做成丸剂1。
实施例5
将5Kg枳椇子果汁粉、5Kg藤茶汁粉(15%)、3Kg番茄粉、21Kg固体果葡糖、2.5Kg果胶、130g三氯蔗糖、125g维生素C钙(抗坏血酸钙)、1Kg异麦芽酮糖醇、10.535Kg麦芽糊精、1Kg柠檬酸、500g二氧化硅、210g水果香精,置于混合机中混合均匀,将混匀后的混合物包装得到粉状固体饮料1;也可将混合物进行制粒后包装得到颗粒状固体饮料2.
实施例6
将2.4Kg蜂蜡与10kg精炼植物油置于配料罐中加热至65±5℃,搅拌溶解,加入38.05Kg精炼植物油,搅拌均匀,保温40±5℃,加入5.4Kg枳椇子提取物、450g藤茶提取物(50%)、5Kg维生素C棕榈酸酯、2.7Kg维生素E、6Kg番茄提取物(20%,油树脂),搅匀后经胶体磨分散并搅拌均匀,得到内容物料液。将内容物料液置于软胶囊压丸机上,用配好的软胶囊壳胶液,进行压丸,经定型、干燥、拣丸等工艺得到软胶囊1。
实施例7
将2Kg小烛树蜡与12kg水飞蓟籽油置于配料罐中加热至65±5℃,搅拌溶解,加入35.28Kg水飞蓟籽油、2Kg番茄提取物(95%,晶体磨粉)、12g维生素E、400g维生素B6、16g维生素C棕榈酸酯、300g迷迭香提取物,搅拌均匀,保温35±5℃,加入1.5Kg枳椇子提取物、6.5Kg藤茶提取物(75%)、搅匀后经100目筛并搅拌均匀,得到内容物料液。将内容物料液置于软胶囊压丸机上,用配好的软胶囊壳胶液,进行压丸,经定型、干燥、拣丸等工艺得到软胶囊2。
实施例8
将12Kg果葡糖浆、25Kg纯化水、7Kg蔗糖置于熬糖罐中,煮沸熬煮搅拌。用5Kg冷纯化水与2Kg果冻粉混合,加入熬糖罐中继续熬煮搅拌,过滤后转入配料罐,75-90℃保温并搅拌。将0.5Kg藤茶粉(25%)、6Kg枳椇子果汁、3Kg番茄果汁、3Kg水混匀后加入配料罐,搅拌乳化均匀。将14g维生素C钾(抗环血酸钾)、0.4g维生素B6、100g柠檬酸,15g柠檬酸钠、8g食用着色剂用3Kg水溶解后,加入配料罐混匀,加入40g水果香精搅拌混匀过滤后包装,灭菌、冷却得到果冻1。
对比例1(空白对照)
实施例3中的枳椇子粉、藤茶提取物、番茄提取物、固体果葡糖、维生素C均用相同重量的预糊化淀粉替换,其余和实施例3中片剂制法相同,得到片剂2。
对比例2(枳椇子对照)
实施例3中的藤茶提取物、番茄提取物、固体果葡糖、维生素C均用相同重量的预糊化淀粉替换,其余和实施例3中片剂制法相同,得到片剂3。
对比例3(枳椇子+藤茶提取物对照)
实施例3中的番茄提取物、固体果葡糖、维生素C均用相同重量的预糊化淀粉替换,其余和实施例3中片剂制法相同,得到片剂4。
对比例4(枳椇子+番茄提取物对照)
实施例3中的藤茶提取物、固体果葡糖、维生素C均用相同重量的预糊化淀粉替换,其余和实施例3中片剂制法相同,得到片剂5。
测试例1:小鼠抗氧化功能试验研究
1.试验药物:
对比例1中的片剂2组合物(空白组,代号A1);
对比例2中的片剂3组合物(枳椇子组,代号B);
对比例3中的片剂4组合物(枳椇子+藤茶提取物组,代号C);
对比例4中的片剂5组合物(枳椇子+番茄提取物组,代号D)。
实施例3中的片剂1组合物(产品组,代号E1);
2.试验方法:
选用11月龄的老龄小鼠,试验前取尾血,测丙二醛MDA值,按MDA水平随机分为:A1组(空白组,片剂2组合物)、B组(枳椇子组,片剂3组合物)、C组(枳椇子+藤茶提取物组,片剂4组合物)、D组(枳椇子+番茄提取物组,片剂5组合物)、E1组(产品组,片剂1组合物),每组8只。
各组灌胃给样品,每天一次,连续30天。试验结束时称量体重后,处死实验小鼠,取肝组织,液氮冷冻,-40℃保存。测定超氧化物歧化酶(SOD)、还原性谷胱甘肽(GSH)、丙二醛(MDA)、和蛋白羰基含量值。
3.试验结果:
小鼠抗氧化功能试验各项结果如下,
由表2数据可知,各组小鼠试验初期、试验中期、及试验终期的体重没有变化,说明产品对小鼠体重没什么影响。
注:aP<0.05vs A1组(空白组),bP<0.05vs B组(枳椇子组),cP<0.05vs C组(枳椇子+藤茶提取物组),dP<0.05vsD组(枳椇子+番茄提取物组)
由表3数据可知,B组(枳椇子组,对比例2,片剂3)对A1组(空白组,对比例1,片剂2)在肝组织SOD活力、蛋白质羰基含量指标,差异性显著;C组(枳椇子+藤茶提取物组,对比例3,片剂4)对B组(枳椇子组)在肝组织MDA、SOD活力指标差异性显著;D(枳椇子+番茄提取物组,对比例4,片剂5)对C组(枳椇子+藤茶提取物组)在肝组织SOD活力和蛋白质羰基含量指标差异性显著,E1组(产品组,实施例3,片剂1)对D(枳椇子+番茄提取物组)在肝组织SOD活力和GSH含量指标差异性显著。说明产品既有抗氧化效果,且组合物之间具有协同作用,能增强整体抗氧化效果。
测试例2:抗氧化功能人体试验研究
1.试验药物:
对比例1中的片剂2组合物(空白组,代号A2组);
实施例3中的片剂1组合物(产品组,代号E2组);
维生素E软胶囊(阳性对照组,代号F组;青岛双鲸药业股份有限公司,国药准字H37023085)
2.试验方法:
选择年龄18~65岁,身体健康状况良好,无明显脑、心、肝、肺、肾、血液疾患,无长期服药史,志愿受试保证配合的人群。排除(1)妊娠或哺乳期妇女,对番茄红素过敏者;(2)合并有心、肝、肾和造血系统等严重疾病患者;(3)短期内服用与受试功能有关的物品,影响对结果的判断者;(4)不符合纳入标准,未按规定服食受试样品,无法判定功效或资料不全影响功效或安全性判断者。
试验采用双盲随机分组、组间和自身两种对照设计。试验共入选70例受试者,受试者按丙二醛(MDA)、超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)水平随机分为3组,其中A2组23例,F组23例,E2组24例。
试食期间保持平日的生活和饮食习惯。连续观察120d,观察试食前后MDA含量、SOD和GSH-Px水平变化等。
3.试验结果:
人体抗氧化功能试验各项结果如下(过程中A2组和E2组各脱除1例):
注:*P<0.05vs试食前,aP<0.05vs A2组,bP<0.05vs F组。
由表4可以看出:E2组(产品组,实施例3,片剂1)在试食试验过程中MDA水平的下降幅度,相对A2组(空白组,对比例1,片剂2)和F组(阳性对照组,维生素E软胶囊,国药准字H37023085)均有显著性差异。
注:*P<0.05vs试食前,aP<0.05vs A2组,bP<0.05vs F组。
由表5数据可知:E2组(产品组,实施例3,片剂1)在试食试验后SOD水平以及试验前后SOD上升幅度,相对A2组(空白组,对比例1,片剂2)和F组(阳性对照组,维生素E软胶囊,国药准字H37023085)均有显著性差异。
注:*P<0.05vs试食前,aP<0.05vs A2组,bP<0.05vs F组。
由表6:E2组(产品组,实施例3,片剂1)在试食试验前后GSH-Px升高幅度,相对A2组(空白组,对比例1,片剂2)和F组(阳性对照组,维生素E软胶囊,国药准字H37023085)均有显著性差异。
以上各组数据表明,产品(E2组,实施例3,片剂1)在人体内具有抗氧化的功能,且效果优于F组(阳性对照组,维生素E软胶囊,国药准字H37023085)。
测试例3:小鼠酒精性肝损伤试验研究
1.试验药物:
纯净水(空白组,代号K组);
实施例3中的片剂1组合物(产品组,代号E3组);
海王金樽片(阳性对照组,代号Y组,深圳市海王健康科技发展有限公司;卫食健字(2002)第0396号)
2.试验方法:
1)选用健康成年的小鼠,18只,分成3组每组6只,空腹分别灌胃0.12ml/10g·bw、0.15ml/10g·bw、0.18ml/10g·bw的52°红星二锅头白酒,根据动物步态和活动情况、醉酒时间、翻正反射情况等,确定小鼠醉酒量0.15ml/10g·bw。
2)选用健康成年的小鼠,40只,每组10只,分成4组,分别为:K组(空白组,灌服纯净水)、M组(模型组,醉酒后灌服纯净水)、E3组(产品组,醉酒后灌服实施例3的片剂1)、Y组(阳性对照组,醉酒后灌食海王金樽片)。
记录实验过程中醉酒时间。试验结束时,处死实验小鼠,取肝组织,液氮冷冻,-40℃保存。测定血清中谷草转氨酶(AST)、谷丙转氨酶(ALT)活力水平,以及肝组织丙二醛(MDA)、还原性谷胱甘肽(GSH)、和甘油三酯(TG)水平。
3.试验结果:
小鼠酒精性肝损伤试验结果如下:
注:*P<0.05vs M组。
通过表7结果可知,不管是小鼠的酒精耐受时间还是酒醉的维持时间,产品组(E3组)和阳性对照组(Y组)均和模型组(M组)有显著差异,具有良好的解酒/缓解酒后症状的作用,且产品组(E3组)优于阳性对照组(Y组),但无差异显著性。
注:*P<0.05vs K组,aP<0.05vs M组,bP<0.01vs M组。
由表8可知,产品组(E3组)、阳性对照组(Y组)对比模型组(M组),在降低谷草转氨酶(AST)和谷丙转氨酶(ALT),保护肝细胞损伤方面有良好的效果,且产品组(E3组)优于阳性对照组(Y组),AST无差异显著性,ALT差异明显。
注:*P<0.05vs K组,aP<0.05vs M组。
由表9可知,产品组(E3组)、阳性对照组(Y组)对比模型组(M组),在肝组织丙二醛(MDA)、还原性谷胱甘肽(GSH)和甘油三酯(TG)指标均有显著差异,说明在保护肝脏、对抗脂肪肝方面有良好的作用。产品组(E3组)和阳性对照组(Y组)间无明显差异。
以上各组数据表明,产品组(E3组,实施例3,片剂1)具有保护酒精性肝损伤的作用,对小鼠醉酒的症状有缓解效果,且效果整体优于阳性对照组。
测试例4:醉酒症状人体试食试验研究
1.试验药物:
实施例3中的片剂1组合物(产品组,代号E4组);
海王金樽片(阳性对照组,代号Y’组,深圳市海王健康科技发展有限公司;卫食健字(2002)第0396号)
2.试验方法:
选择浙江某市男性自愿者39名,年龄在35~40岁之间,进行体检证实无任何器质性疾病和酒精过敏症状。
试验过程:
1)醉酒量测试试验(试验编号1))
所有受试人员试验前未服用任何产品,在指定时间进食泸州老窖(52°白酒)和准备的食物,至酒醉,观察受试者动作,言语等,记录醉酒嗜睡时间,以及酒醒后感受,醉酒症状完全消失时间等,且在醉酒2h测定静脉血液中乙醇浓度。
2)醒酒试验(试验编号2))
上述酒量测试试验进行一周后,在同一地点、时间进行醒酒试验,确认健康状况良好,排除感冒生病等受试者。
将受试者随机分成2组,分别为:①产品组(E4组)20人:醉酒前30min先温水吞服实施例3的片剂1,醉酒后如口渴只喝纯净水,不进食其他任何食物或饮品;②阳性对照组(Y’组)19人:醉酒前30min先温水吞服海王金樽片,醉酒后如口渴只喝纯净水,不进食其他任何食物或饮品。在与上次同样指定时间,饮用各自上次记录醉酒量的相同白酒,进食相同品种相同量的食物,观察受试者动作,言语等,记录醉酒嗜睡时间,以及酒醒后感受,醉酒症状完全消失时间等,且在醉酒2h测定静脉血液中乙醇浓度。
3.试验结果:
小鼠酒精性肝损伤试验结果如下:
注:*P<0.05vs试验1)。
通过表9结果可知,产品组(E4组)和阳性对照组(Y’组)可一定程度的降低酒后2h静脉血液中乙醇的浓度,但效果不明显;两组均可以缩短醉酒的嗜睡时间和酒后症状的完全恢复时间;产品组(E4组)对醉酒睡醒后的头晕症状也有明显改善,说明产品对缓解酒后症状有良好的效果。
显然,上述实施例仅仅是为清楚地说明所作的举例,而并非对实施方式的限定。对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引伸出的显而易见的变化或变动仍处于本发明创造的保护范围之中。
Claims (10)
1.一种组合物,包含:枳椇子0.2~280重量份;番茄0.2~300重量份;藤茶0.1~150重量份。
2.根据权利要求1所述的组合物,其包含:枳椇子0.3~250重量份;番茄0.25~250重量份;藤茶0.15~120重量份。
3.根据权利要求1或2所述的组合物,其还包含选自维生素C和/或其盐和/或其衍生物,果葡糖(糖粉或/和糖浆),葡萄糖,果糖,维生素B6,维生素E中的至少一种;优选地,所述组合物还包含维生素C。
4.根据权利要求3所述的组合物,其特征在于如下1)至4)中的一项或多项:
1)所述维生素C和/或其盐和/或其衍生物为0.005~15重量份;更优选地,所述维生素C和/或其盐和/或其衍生物为0.01~10重量份;
2)所述果葡糖和/或果糖和/或葡萄糖为1~600重量份,优选为4~400重量份;
3)所述维生素B6为0.0004~0.3重量份,优选为0.0005~0.2重量份;
4)所述维生素E为0.001~5重量份,优选为0.003~3重量份。
5.根据权利要求1至4中任一项所述的组合物,其还包含辅料;优选地,所述辅料选自稀释剂、稳定剂、抗氧化剂、防腐剂、螯合剂、粘合剂、助流剂、矫味剂、着色剂、润湿剂、抗结剂、填充剂、润滑剂、包衣剂(或被膜剂)、崩解剂和载体中的至少一种。
6.一种药物或食品,包含权利要求1至5任一项所述的组合物;优选地,所述食品为食品;优选地,所述药物或食品的剂型为饮料、糖果、果冻、片剂、胶囊剂、固体饮料。
7.根据权利要求1或2所述的组合物;其特征在于:
1)所述枳椇子包含枳椇子鲜果以及由其加工而成的枳椇子果汁(原汁和/或浓缩汁)、枳椇子果酱、枳椇子果汁粉、枳椇子粉、枳椇子提取物中的至少一种;
优选的所述枳椇子包含枳椇子果汁、枳椇子粉、枳椇子提取物中的至少一种;
2)所述番茄包含番茄鲜果以及由其加工而成的番茄果汁(原汁和/或浓缩汁)、番茄果酱、番茄粉、番茄提取物中的至少一种;
优选的所述番茄包含番茄果汁、番茄粉、番茄提取物中的至少一种;
3)所述藤茶包含鲜藤茶以及由其嫩叶加工而成的藤茶汁(原汁和/或浓缩汁)、藤茶汁粉、藤茶、藤茶粉、藤茶提取物中的至少一种;
优选的所述藤茶包含藤茶汁、藤茶粉、藤茶提取物中的至少一种。
8.制备权利要求1至5任一项所述组合物的方法为如下的方法1、方法2;其中,
方法1包括如下步骤:
(1)将枳椇子、番茄分别经榨汁、均质、过滤、离心、加热、溶解中的至少一种工艺处理后,与藤茶,选自维生素C和/或其盐和/或其衍生物、果葡糖、葡萄糖、果糖、维生素B6、维生素E中的至少一种以及选自稀释剂、螯合剂、稳定剂、抗氧化剂中的至少一种进行溶解混合,经溶解、离心、过滤、加热、均质中的至少一种工艺处理,得混合物;
(2)将步骤(1)得到的混合物,与选自稀释剂、螯合剂、稳定剂、抗氧化剂、防腐剂、螯合剂、矫味剂、着色剂中的至少一种混合溶解或分步混合溶解,经离心、过滤、均质、冷藏、沉淀、灭菌中的至少一种工艺处理,得混合物;
优选地,方法1中,枳椇子包含枳椇子鲜果、枳椇子果汁、枳椇子提取物中的至少一种;番茄包含番茄鲜果、番茄果汁、番茄提取物中的至少一种;藤茶包含藤茶汁、藤茶提取物中的至少一种。还包括选自维生素C、维生素C盐、果葡糖、葡萄糖、果糖、维生素B6中的至少一种共同混合。
方法2包括如下步骤:
将枳椇子、番茄、藤茶,与选自稀释剂、稳定剂、抗氧化剂、防腐剂、粘合剂、助流剂、矫味剂、着色剂、润湿剂、抗结剂、填充剂、润滑剂、包衣剂(或被膜剂)、崩解剂和载体中的至少一种混合或分步混合。
优选地,方法2中,还包括加入选自维生素C和/或其盐和/或其衍生物,果葡糖,葡萄糖,果糖,维生素B6、维生素E中的至少一种共同混合。
9.权利要求1至5任一所述组合物在制备抗氧化和/或辅助抗氧化的药物中的用途或者在制备酒精性肝损伤和/或辅助治疗酒精性肝损伤药物中的用途。
10.权利要求1至6中任一所述组合物在制备抗氧化的食品中的用途或者在制预防和/或改善由饮酒等引起的头晕、嗜睡、呕吐等不适症状的食品中的用途或者在制备预防和/或改善酒精性肝损伤的食品中的用途;
优选地,所述食品为保健食品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110122481.3A CN112691150A (zh) | 2021-01-28 | 2021-01-28 | 一种组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110122481.3A CN112691150A (zh) | 2021-01-28 | 2021-01-28 | 一种组合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112691150A true CN112691150A (zh) | 2021-04-23 |
Family
ID=75516317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110122481.3A Pending CN112691150A (zh) | 2021-01-28 | 2021-01-28 | 一种组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112691150A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114631632A (zh) * | 2022-04-20 | 2022-06-17 | 广东省刺梨产业研究院 | 一种护肝解酒的刺梨组合物及其制剂与应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101766636A (zh) * | 2008-12-31 | 2010-07-07 | 克科 | 解酒醒酒组合物 |
CN103598329A (zh) * | 2013-11-26 | 2014-02-26 | 成冠辉 | 一种西红柿解酒酸奶的快速制备方法 |
CN103948028A (zh) * | 2014-04-20 | 2014-07-30 | 江苏康缘药业股份有限公司 | 一种具有缓解肝损伤作用的组合物及其制备方法及含量测定方法 |
CN107007813A (zh) * | 2017-05-27 | 2017-08-04 | 云南德彩堂生物医药科技有限公司 | 一种高效解酒护肝组合物,其制备方法和应用 |
CN112007092A (zh) * | 2020-09-29 | 2020-12-01 | 北京佳福瑞生物科技有限公司 | 一种解酒组合物及其制备方法 |
-
2021
- 2021-01-28 CN CN202110122481.3A patent/CN112691150A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101766636A (zh) * | 2008-12-31 | 2010-07-07 | 克科 | 解酒醒酒组合物 |
CN103598329A (zh) * | 2013-11-26 | 2014-02-26 | 成冠辉 | 一种西红柿解酒酸奶的快速制备方法 |
CN103948028A (zh) * | 2014-04-20 | 2014-07-30 | 江苏康缘药业股份有限公司 | 一种具有缓解肝损伤作用的组合物及其制备方法及含量测定方法 |
CN107007813A (zh) * | 2017-05-27 | 2017-08-04 | 云南德彩堂生物医药科技有限公司 | 一种高效解酒护肝组合物,其制备方法和应用 |
CN112007092A (zh) * | 2020-09-29 | 2020-12-01 | 北京佳福瑞生物科技有限公司 | 一种解酒组合物及其制备方法 |
Non-Patent Citations (2)
Title |
---|
于文利等: "两种抗氧化剂协同增效及其抗衰老的研究", 《中国油脂》 * |
刘广田: "《养肝就是养命》", 30 September 2016, 中医古籍出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114631632A (zh) * | 2022-04-20 | 2022-06-17 | 广东省刺梨产业研究院 | 一种护肝解酒的刺梨组合物及其制剂与应用 |
CN114631632B (zh) * | 2022-04-20 | 2024-06-04 | 广东省刺梨产业研究院 | 一种护肝解酒的刺梨组合物及其制剂与应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20180104299A1 (en) | Use of saffron and/or safranal and/or crocin and/or picrocrocin and/or derivatives thereof as a satiation agent for the treatment of obesity | |
JP5937596B2 (ja) | 活性型フラボノイド化合物の含量が増加されたウルシ抽出物及びその製造方法 | |
PB Gollucke et al. | Polyphenols: A nutraceutical approach against diseases | |
CN101296693B (zh) | 持久力提高剂 | |
TWI721248B (zh) | 提高耐力表現之抗疲勞組合物 | |
CN102038260B (zh) | 中药解酒保健饮料及其制备方法 | |
CN103229884A (zh) | 一种姜黄素保健硬糖及其制备方法 | |
JP5261808B2 (ja) | 脂肪蓄積抑制剤、医薬品及び脂肪蓄積抑制作用を新たに付与する方法 | |
Arumugam et al. | Fruits and vegetables as Superfoods: Scope and demand | |
CN101766274B (zh) | 含竹叶黄酮的抗氧化功能食品组合物 | |
KR101488612B1 (ko) | 흑색 식품소재를 함유하는 건강식품 및 약학적 조성물 | |
KR20160144791A (ko) | 여성 갱년기 증상 개선용 조성물 | |
US20040219238A1 (en) | Remedies | |
KR101093998B1 (ko) | 숙취해소 및 간기능 개선용 기능성 조성물 | |
KR20160141027A (ko) | 아위버섯 물 추출물을 유효성분으로 함유하는 대사성질환의 예방 및 치료용 약학적 조성물 또는 건강기능성식품 | |
KR101565964B1 (ko) | 아위버섯의 물 추출물을 유효성분으로 함유하는 고지혈증 예방 또는 치료용 조성물 | |
KR20130097537A (ko) | 강황, 석창포, 원지의 열수추출물의 혼합물을 유효성분으로 포함하는 인지력 및 기억력 향상용 조성물 | |
CN112691150A (zh) | 一种组合物及其制备方法和应用 | |
KR101859166B1 (ko) | 인삼이 함유된 한약재 추출물을 유효성분으로 함유하는 숙취 해소용 조성물 | |
CN101884408B (zh) | 一种银杏叶浸提液及其制备方法 | |
KR20170086198A (ko) | 발효 한약재와 식이섬유를 포함하는 다이어트 고형차 제조방법 및 이로부터 제조된 고형차 | |
WO2005094858A1 (ja) | 抗糖尿病用組成物 | |
KR20110051543A (ko) | 블루베리 발효 추출물을 유효성분으로 함유하는 비만의 예방 또는 치료용 조성물 | |
KR20080033717A (ko) | 꿀과 생약재를 이용한 건강보조식품 조성물과 그 제조방법 | |
KR20050100890A (ko) | 오가피 및 녹차 추출물을 함유하는 숙취해소용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210423 |
|
RJ01 | Rejection of invention patent application after publication |